Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.

Phase 2

Terminated

• Conditions: Cirrhosis, Liver; Ascites Hepatic
• Interventions: Drug: Placebo; Drug: Ularitide

• Registration Number: NCT04311489
• Lead Sponsor: University of Aarhus

Brief Summary

This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide on the renal response in patients with liver cirrhosis and refractory ascites for a maximum exposure duration of 48 hours, through a randomized, placebo-controlled, double-blind, single-center trial.

Detailed Description

The investigators hypothesize that ularitide infusion is more effective than placebo to induce and maintain clinically meaningful natriuresis and diuresis in patients with liver cirrhosis and refractory ascites.

Participants will be given ularitide or placebo intravenously while hospitalized at Department of Hepatology and Gastroenterology at Aarhus University Hospital. During the hospitalization blood and urine samples are frequently collected.

30 ng/kg/min is the starting dosage for all participants. Depending on effects and/or side effects, ULA04 is designed to individualize treatment doses by up- and/or downtitration of the infusion dose within a predefined dose range. Relevant safety precautions are incorporated in the study design and treatment will be prematurely discontinued if a pre-defined stopping criteria presents.

Patients will be followed up for the appearance of serious adverse events 30 days after the treatment.

If a separate written consent is given by the participants, additional blood and urine samples will be collected and stored in a biobank for future research.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-03-12
• Study First Submitted QC: 2020-03-16
• Study First Posted: 2020-03-17
• Study Start: 2020-08-01
• Status Verified: 2022-05
• Primary Completion: 2022-11-30
• Study Completion: 2022-11-30
• Last Update Submitted: 2023-05-16
• Last Update Posted: 2023-05-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• Men and women >18 years
• Liver cirrhosis confirmed by fibroscan (>20 kPa), or by imaging with signs of an irregular liver surface with collaterals, or clinically by cirrhosis stigmata
• Refractory ascites Definition: failure to respond to or intolerance to high dose diuretics (spironolactone up to 400mg/day and furosemide up to 160mg/day) and early ascites recurrence (reappearance of grade 2 or 3 ascites within 4 weeks of initial mobilization or ≥2 paracentesis within last 3 months)
• Urine sodium excretion <60 mmol/24 hour
• Serum creatinine <150 µmol/L
• Child-Turcotte-Pugh score of B or C (<13)
• Bilirubin <150 µmol/L
• Prothrombin time (PP) 0.20-0.60 (INR 1.3-2.5)
• Systolic blood pressure ≥95 mmHg
• Written informed consent to participate in the clinical trial

Read More

Exclusion Criteria

• Gastrointestinal bleeding within 2 weeks prior to inclusion
• Proteinuria >500 mg/day
• Hemoglobin <5.5 mmol/L
• Spontaneous bacterial peritonitis within 2 weeks prior to inclusion
• Loculated ascites
• Hepatic encephalopathy grade 2-4 (West-Haven classification)
• Obstructive uropathy
• Primary kidney disease
• Known diagnosis of congestive heart failure
• Known diagnosis of acute-on-chronic liver failure
• Known diagnosis of systemic inflammatory response syndrome
• Acute infections by known diagnosis and/or antibiotic treatment
• Known HIV infection
• Known allergy to the investigational drug or other natriuretic peptides
• Treatment with dobutamine, levosimendan, milrinone, any phosphodiesterase inhibitor, octreotide, midodrine, vasopressin, dopamine or other vasopressors within 2 weeks prior to inclusion
• Nephrotoxic drugs within 1 month prior to inclusion
• Fertile women not using contraception, either an intrauterine device or hormonal contraception
• Positive pregnancy test in pre-menopausal women or in breast-feeding women
• Participation in an interventional clinical drug trial within 1 month prior to inclusion
• Legal incapacity or limited legal capacity
• Patients who are employees or relatives of the investigator

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Matching placebo. Continuous IV infusion for 48 hours.
Ularitide	Ularitide	Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.

Primary Outcome Measures

Name	Time	Method
Absolute and relative change in sodium excretion rate.	After 24 hours and at termination of treatment (up to 48 hours)
Absolute and relative change in urine volume.	After 24 hours and at termination of treatment (up to 48 hours)
Change of absolute body weight.	At termination of treatment (up to 48 hours)

Secondary Outcome Measures

Name	Time	Method
Absolute and relative change in urine volume.	After 2 hours and 4 hours of treatment and at 6 hours post-treatment follow-up
Number of responders in the ularitide group versus the placebo group, defined by:	Throughout the treatment period. Latest measure at termination of treatment (up to 48 hours)	Urine volume increase of ≥100 % versus baseline, urine volume increase ≥50 % versus baseline, natriuresis increase by ≥100 % versus baseline and/or body weight reduction by ≥2 kg versus baseline.
Absolute and relative change in sodium excretion rate.	After 2 hours and 4 hours of treatment and at 6 hours post-treatment follow-up
Absolute and relative change in plasma cyclic guanosine monophosphate (cGMP) concentration.	Throughout the treatment period. Latest measure at 6 hours post-treatment follow-up
Absolute and relative change in waist circumference.	After 24 hours and at termination of treatment (up to 48 hours)
Absolute and relative change in serum creatinine.	After 24 hours and at termination of treatment (up to 48 hours)
Absolute and relative change in estimated glomerular filtration rate (eGFR).	After 24 hours and at termination of treatment (up to 48 hours)
Absolute and relative change in plasma and urine osmolalities.	Throughout the treatment period. Latest measure at 6 hours post-treatment follow-up
Absolute and relative change in GFR-24h-Crea (Glomerular filtration rate based on 24-hour creatinine clearance).	After 24 hours and 48 hours of treatment
Absolute and relative change in hematocrit.	After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up
Absolute and relative change in plasma copeptin concentration.	After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up
Absolute and relative change in plasma renin concentration.	After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up
Absolute and relative change in plasma angiotensin concentration.	After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up
Absolute and relative change in plasma aldosterone concentration.	After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up

Trial Locations

Locations (1)

Department of Hepatology and Gastroenterology, Aarhus University Hospital; 🇩🇰 Aarhus, Central Denmark Region, Denmark